FIELD: biotechnology; medicine; agriculture.
SUBSTANCE: invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture to develop gene therapy preparations. A gene therapy DNA vector based on the VTvaf17 gene therapy DNA vector, having a target gene selected from a group of genes IFNB1, IFNA14, IFNA2, IL12A, IL12B to increase the level of expression of this target gene in the human and animal body, wherein the gene therapy DNA vector VTvaf17-IFNB1, or VTvaf17-IFNA14, or VTvaf17-IFNA2, or VTvaf17-IL12A, or VTvaf17-IL12B has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, respectively. Each of the created gene therapy DNA vectors: VTvaf17-IFNB1, or VTvaf17-IFNA14, or VTvaf17-IFNA2, or VTvaf17-IL12A, or VTvaf17-IL12B due to the limited size of the vector part of VTvaf17, not exceeding 3200 base pairs, has the ability to efficiently penetrate into cells and to express the target gene cloned in it, selected from the group of genes IFNB1, IFNA14, IFNA2, IL12A, IL12B respectively.
EFFECT: gene-therapeutic DNA-vector contains no nucleotide sequences of viral origin and antibiotic-resistant genes are absent, providing the possibility of its safe application for genetic therapy of human and animals.
16 cl, 17 dwg, 20 ex
